BioCentury | Nov 1, 2019
Product Development

Vertex’s triple therapy will reshape the landscape of cystic fibrosis trials

FDA approval of Vertex’s long-awaited triple therapy for cystic fibrosis is likely to seal the company’s dominance in the indication for years to come, with competitive threats barely touching the horizon. Moreover, uptake of the...
BC Extra | Aug 5, 2019
Company News

Aug. 5 Company Quick Takes: Briefing docs for Descovy cast doubt on full PrEP approval; plus Alnylam, Provention and more

FDA questions Descovy as PrEP in cis women Briefing documents released ahead of the Aug. 7 Antimicrobial Drugs Advisory Committee meeting for Descovy emtricitabine/tenofovir alafenamide from Gilead Sciences Inc. (NASDAQ:GILD) indicate that FDA is uncertain...
BC Week In Review | Mar 29, 2019
Clinical News

Proteostasis sinks after Phase I data for CF triplet therapy

Proteostasis lost $2.76 (68%) to $1.31 on Monday after reporting Phase I data for its triplet cystic fibrosis therapy that lagged behind Phase III data of triple combination CF therapies from Vertex. Proteostasis Therapeutics Inc....
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BC Week In Review | Oct 26, 2018
Financial News

Proteostasis raises $74.3M on the heels of positive CF data

Proteostasis Therapeutics Inc. (NASDAQ:PTI) raised $74.3 million late Oct. 23 through the sale of 11 million shares at $6.75 in a bumped-up follow-on underwritten by Leerink, Piper Jaffray, Cantor Fitzgerald and H.C. Wainwright. The price...
BC Week In Review | Oct 19, 2018
Clinical News

Proteostasis' doublet CF therapy improves lung function in Phase I

Proteostasis Therapeutics Inc. (NASDAQ:PTI) reported that its doublet cystic fibrosis therapy improved percent predicted forced expiratory volume in 1 second (ppFEV1) and sweat chloride levels in a Phase I trial. The doublet therapy comprised CF...
BC Extra | Oct 18, 2018
Clinical News

Big gain for Proteostasis on Phase I data for CF doublet

Proteostasis Therapeutics Inc. (NASDAQ:PTI) jumped $8.46 (448%) to $10.35 on Thursday after reporting that its doublet cystic fibrosis therapy improved percent predicted forced expiratory volume in 1 second (ppFEV1) and sweat chloride levels in a...
BC Innovations | May 3, 2018
Emerging Company Profile

Come together

Aelin Therapeutics N.V. is developing first-in-class synthetic peptides that could treat antibiotic-resistant Gram-negative infections by inducing toxic protein aggregation within bacterial cells. By harnessing a novel mechanism of action that disrupts proteostasis, Aelin could circumvent...
BC Week In Review | Mar 23, 2018
Financial News

Proteostasis withdraws offering after short report

Respiratory company Proteostasis Therapeutics Inc. (NASDAQ:PTI) withdrew its proposed follow-on late on March 20, citing market conditions. Proteostasis had proposed March 19 after market hours to sell 9 million shares. The company lost $1.83 (26%)...
BC Extra | Mar 21, 2018
Financial News

Proteostasis withdraws offering after short report

Proteostasis Therapeutics Inc. (NASDAQ:PTI) withdrew its proposed follow-on Tuesday evening, citing market conditions. Proteostasis had proposed Monday after market hours to sell 9 million shares. The company lost $1.83 (26%) to $5.16 on Tuesday, then...
Items per page:
1 - 10 of 73
BioCentury | Nov 1, 2019
Product Development

Vertex’s triple therapy will reshape the landscape of cystic fibrosis trials

FDA approval of Vertex’s long-awaited triple therapy for cystic fibrosis is likely to seal the company’s dominance in the indication for years to come, with competitive threats barely touching the horizon. Moreover, uptake of the...
BC Extra | Aug 5, 2019
Company News

Aug. 5 Company Quick Takes: Briefing docs for Descovy cast doubt on full PrEP approval; plus Alnylam, Provention and more

FDA questions Descovy as PrEP in cis women Briefing documents released ahead of the Aug. 7 Antimicrobial Drugs Advisory Committee meeting for Descovy emtricitabine/tenofovir alafenamide from Gilead Sciences Inc. (NASDAQ:GILD) indicate that FDA is uncertain...
BC Week In Review | Mar 29, 2019
Clinical News

Proteostasis sinks after Phase I data for CF triplet therapy

Proteostasis lost $2.76 (68%) to $1.31 on Monday after reporting Phase I data for its triplet cystic fibrosis therapy that lagged behind Phase III data of triple combination CF therapies from Vertex. Proteostasis Therapeutics Inc....
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BC Week In Review | Oct 26, 2018
Financial News

Proteostasis raises $74.3M on the heels of positive CF data

Proteostasis Therapeutics Inc. (NASDAQ:PTI) raised $74.3 million late Oct. 23 through the sale of 11 million shares at $6.75 in a bumped-up follow-on underwritten by Leerink, Piper Jaffray, Cantor Fitzgerald and H.C. Wainwright. The price...
BC Week In Review | Oct 19, 2018
Clinical News

Proteostasis' doublet CF therapy improves lung function in Phase I

Proteostasis Therapeutics Inc. (NASDAQ:PTI) reported that its doublet cystic fibrosis therapy improved percent predicted forced expiratory volume in 1 second (ppFEV1) and sweat chloride levels in a Phase I trial. The doublet therapy comprised CF...
BC Extra | Oct 18, 2018
Clinical News

Big gain for Proteostasis on Phase I data for CF doublet

Proteostasis Therapeutics Inc. (NASDAQ:PTI) jumped $8.46 (448%) to $10.35 on Thursday after reporting that its doublet cystic fibrosis therapy improved percent predicted forced expiratory volume in 1 second (ppFEV1) and sweat chloride levels in a...
BC Innovations | May 3, 2018
Emerging Company Profile

Come together

Aelin Therapeutics N.V. is developing first-in-class synthetic peptides that could treat antibiotic-resistant Gram-negative infections by inducing toxic protein aggregation within bacterial cells. By harnessing a novel mechanism of action that disrupts proteostasis, Aelin could circumvent...
BC Week In Review | Mar 23, 2018
Financial News

Proteostasis withdraws offering after short report

Respiratory company Proteostasis Therapeutics Inc. (NASDAQ:PTI) withdrew its proposed follow-on late on March 20, citing market conditions. Proteostasis had proposed March 19 after market hours to sell 9 million shares. The company lost $1.83 (26%)...
BC Extra | Mar 21, 2018
Financial News

Proteostasis withdraws offering after short report

Proteostasis Therapeutics Inc. (NASDAQ:PTI) withdrew its proposed follow-on Tuesday evening, citing market conditions. Proteostasis had proposed Monday after market hours to sell 9 million shares. The company lost $1.83 (26%) to $5.16 on Tuesday, then...
Items per page:
1 - 10 of 73